News

Nuplazid (pimavanserin), an approved therapy for treating hallucinations associated with Parkinson’s disease psychosis, is generally safe and well-tolerated in the long run, and may be associated with reduced mortality in this particular patient population, findings from a long-term extension study suggest. The results were presented at the…

The variability and abundance of gut bacteria are associated with several early risk markers of Parkinson’s disease, particularly those related to motor impairments and constipation, study finds. Future studies investigating the impact of gut bacteria composition on the risk of Parkinson’s and on its early manifestations are…

High blood levels of uric acid, a powerful antioxidant, are linked to an increased risk of levodopa-induced dyskinesia in men with Parkinson’s disease, study finds. The study, “Sex-specific association of urate and levodopa-induced dyskinesia in Parkinson’s disease,” was published in the European Journal of…

Most people with late-stage Parkinson’s disease showed benefit from continued treatment with subthalamic deep brain stimulation (STN-DBS) in a small study in Italy. The researchers also provided an algorithm intended to help guide treatment decisions for those with late-stage disease. Their study, “Should We Consider Deep…

People carrying gene variants that lower leucine-rich repeat kinase 2 (LRRK2) levels — an enzyme whose mutated form is one of the most common genetic causes of Parkinson’s disease — live as long as those without such variants, and show no related lung, liver or kidney damage, results of a large genetic study…

Two compounds with hormone-like effects — prostaglandin E1 (PGE1) and prostaglandin A1 (PGA1) — may help to increase dopamine levels in the brain and slow Parkinson’s progression by activating a protein, called Nurr1, that supports dopaminergic neurons, a study reports. The study, “…

COVID-19 infection appears to worsen some symptoms of Parkinson’s disease, requiring adjustments to therapy, according to a recent case study. The study, “Effects of COVID-19 on Parkinson’s disease clinical features: a community-based case-control study,”  was published in the journal Movement Disorders. SARS-CoV-2, the strain of coronavirus…

Accure Therapeutics announced its opening, supported by €7.6 million (about $8.1 million) in Series A funding. The Barcelona, Spain-based pharmaceutical company will focus on developing treatment candidates for central nervous system (CNS) disorders such as Parkinson’s disease. The funding round was led by Alta Life Sciences, and…

Cognitive abilities and problems with freezing of gait in people with Parkinson’s disease do not seem to be significantly related, new research indicates. The study, “Cognitive function in people with and without freezing of gait in Parkinson’s disease,” was published in npj Parkinson’s Disease. Freezing is a relatively…

Seelos Therapeutics announced it is beginning, earlier than expected, a preclinical study into its investigational gene therapy candidate for Parkinson’s disease called SLS-004. The exact nature of this early research work was not detailed in a press release. Nerve cell damage in Parkinson’s is caused by the buildup of toxic forms…